Cited by 1,858HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 65 of the 70 references it cites were found in a registry or an index.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Open access

Nagata, Yoichi, Lan, Keng-Hsueh, Zhou, Xiaoyan, Tan, Ming, Esteva, Francisco J., Sahin, Aysegul A., Klos, Kristine S., Li, Ping, Monia, Brett P., Nguyen, Nina T., Hortobagyi, Gabriel N., Hung, Mien-Chie, Yu, Dihua·2004·Cancer Cell

DOI 10.1016/j.ccr.2004.06.022

Open this paper in CoChat — free account Open PDF

Abstract

The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab response is poorly understood. Here we report that PTEN activation contributes to trastuzumab's antitumor activity. Trastuzumab treatment quickly increased PTEN membrane localization and phosphatase activity by reducing PTEN tyrosine phosphorylation via Src inhibition. Reducing PTEN in breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast cancers had significantly poorer responses to trastuzumab-based therapy than those with normal PTEN. Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.06.022

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,018
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,637
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

Flagged first, then by citations

Show all 70 references

5 of the 70 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo, Am. J. Pathol., 151, 1523

Sorted by citations

Items 501–600 of 1,001

PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Stern, H. M., Gardner, H., Burzykowski, T., Elatre, W. A., O'Brien, C. L., Lackner, M. R., Pestano, G. A., Santiago, A., Villalobos, I. E., EIERMANN, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2993 · Cited by 70
PTEN modulators: a patent review
Boosani, C. S., & Agrawal, D. K. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.768985 · Cited by 71
Beyond trastuzumab: New treatment options for HER2-positive breast cancer
Saini, K. S., Azim, H. A., Metzger, O., Loi, S., Sotiriou, C. P., de Azambuja, E., & Piccart, M. J. (2011) · The Breast · doi:10.1016/s0960-9776(11)70289-2 · Cited by 71
Emerging therapeutic targets in metastatic progression: A focus on breast cancer
Li, Z., & Kang, Y. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.003 · Cited by 71
Catecholamine-Induced β2-Adrenergic Receptor Activation Mediates Desensitization of Gastric Cancer Cells to Trastuzumab by Upregulating MUC4 Expression
Shi, M., Yang, Z., Hu, M., Liu, D., Hu, Y., Qian, L., Zhang, W., Chen, H., Guo, L., Yu, M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202364 · Cited by 73
Stemming Resistance to HER-2 Targeted Therapy
Bedard, P. L., Cardoso, F., & Piccart, M. J. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9116-x · Cited by 68
Systems pathology—taking molecular pathology into a new dimension
Faratian, D., Clyde, R. G., Crawford, J. W., & Harrison, D. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.102 · Cited by 71
ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines
Ginestier, C., Adélaı̈de, J., Gonçalvès, A., Repellini, L., Sircoulomb, F., Letessier, A., Finetti, P., Geneix, J., Charafe‐Jauffret, E., Bertucci, F., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210528 · Cited by 69
IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
Ikink, G. J., Boer, M., Bakker, E. R. M., & Hilkens, J. (2016) · Nature Communications · doi:10.1038/ncomms13567 · Cited by 69
Signal Transducer and Activator of Transcription 5b, c-Src, and Epidermal Growth Factor Receptor Signaling Play Integral Roles in Estrogen-Stimulated Proliferation of Estrogen Receptor-Positive Breast Cancer Cells
Fox, E. M., Bernaciak, T. M., Wen, J., Weaver, A. M., Shupnik, M. A., & Silva, C. M. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0419 · Cited by 68
Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
Wu, X., Yang, H., Yu, X., & Qin, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1012552 · Cited by 76
Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance
Nahta, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799320691 · Cited by 68
Personalized therapies in the cancer "omics" era
Ocaña, A., & Pandiella, A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-202 · Cited by 68
HER2 breast cancer therapies: a review
Modi, S., & Murphy, C. G. (2009) · Biologics · doi:10.2147/btt.2009.3250 · Cited by 69
AKT signaling in ERBB2-amplified breast cancer
Carmona, F. J., Montemurro, F., Kannan, S., Rossi, V., Verma, C. S., Baselga, J. M., & Scaltriti, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.013 · Cited by 70
MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway
Amini‐Farsani, Z., Sangtarash, M. H., Shamsara, M., & Teimori, H. (2017) · Cytotechnology · doi:10.1007/s10616-017-0134-z · Cited by 68
Stem Cells in Normal Development and Cancer
D'Angelo, R. C., & Wicha, M. S. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385071-3.00006-x · Cited by 68
Recent advances in novel targeted therapies for HER2-positive breast cancer
Murphy, C. G., & Morris, P. G. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328352d292 · Cited by 67
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Bekaii‐Saab, T., Wesolowski, R., Ahn, D. H., Wu, C. S.-Y., Mortazavi, A., Lustberg, M. B., Ramaswamy, B., Fowler, J. M., Wei, L., Overholser, J. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3997 · Cited by 67
CDK4/6 inhibitors: a brief overview and prospective research directions
Adon, T., Shanmugarajan, D., & Kumar, H. Y. (2021) · RSC Advances · doi:10.1039/d1ra03820f · Cited by 67
Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer
Le, X., Almeida, M. I., Mao, W., Spizzo, R., Rossi, S., Nicoloso, M. S., Zhang, S., Wu, Y., Călin, G. A., & Bast, R. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041170 · Cited by 69
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance
Veeraraghavan, J., Angelis, C. D., Reis-Filho, J. S., Pascual, T., Prat, A., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2017) · The Breast · doi:10.1016/j.breast.2017.06.022 · Cited by 67
Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles
Colzani, B., Pandolfi, L., Hoti, A., Iovene, P. A., Natalello, A., Avvakumova, S., Colombo, M., & Prosperi, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s152742 · Cited by 67
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Perez, E. A., de Haas, S. L., EIERMANN, W., Barrios, C. H., Toi, M., Im, Y., Conte, P., Martín, M., Pieńkowski, T., Pivot, X. B., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5687-0 · Cited by 67
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
Padmanabhan, R., Kheraldine, H., Meskin, N., Vranić, S., & Moustafa, A. A. (2020) · Cancers · doi:10.3390/cancers12030636 · Cited by 65
Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
De, P. K. R., Hasmann, M., & Leyland-Jones, B. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.006 · Cited by 66
Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
Hortobágyi, G. N. (2015) · Neoplasia · doi:10.1016/j.neo.2015.01.005 · Cited by 67
Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
Blancafort, A., Giró‐Perafita, A., Oliveras, G., Palomeras, S., Turrado, C., Campuzano, Ó., Carrión-Salip, D., Massaguer, A., Brugada, R., Palafox, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131241 · Cited by 66
New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
Abramson, V. G., & Arteaga, C. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1947 · Cited by 66
V‐ATPase inhibition overcomes trastuzumab resistance in breast cancer
von Schwarzenberg, K., Lajtos, T., Simon, L., Müller, R., Vereb, G., & Vollmar, A. M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.08.011 · Cited by 65
In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Rosa, R., Monteleone, F., Zambrano, N., & Bianco, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113209990226 · Cited by 67
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 64
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
Lv, Q., Meng, Z., Yu, Y., Jiang, F., Guan, D., Liang, C., Zhou, J., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122095 · Cited by 66
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
Wang, X., Cao, X., Sun, R., Tang, C., Tzankov, A., Zhang, J., Manyam, G. C., Xiao, M., Miao, Y., Jabbar, K. J., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.03.002 · Cited by 65
Cyclin E as a prognostic and predictive marker in breast cancer
Hunt, K. K., & Keyomarsi, K. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.007 · Cited by 65
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 64
Linking somatic genetic alterations in cancer to therapeutics
Stuart, D. D., & Sellers, W. R. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.001 · Cited by 66
ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells
Hawthorne, V. S., Huang, W.-C., Neal, C. L., Tseng, L.-M., Hung, M., & Yu, D. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0316 · Cited by 70
FGFR2 as a Molecular Target in Endometrial Cancer
Byron, S. A., & Pollock, P. M. (2009) · Future Oncology · doi:10.2217/14796694.5.1.27 · Cited by 64
Targeting stem cells in the realm of drug-resistant breast cancer
Dey, P., Rathod, M., & De, A. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s189224 · Cited by 64
Viruses – seeking and destroying the tumor program
O’Shea, C. C. (2005) · Oncogene · doi:10.1038/sj.onc.1209047 · Cited by 65
Dual HER2-targeted approaches in HER2-positive breast cancer
Ahn, E. R., & Vogel, C. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1781-y · Cited by 64
Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options
Burnett, J., Körkaya, H., Ouzounova, M., Jiang, H., Conley, S. J., Newman, B. W., Sun, L., Connarn, J. N., Chen, C., Zhang, N., et al. (2015) · Scientific Reports · doi:10.1038/srep15821 · Cited by 64
A prospect of cell immortalization combined with matrix microenvironmental optimization strategy for tissue engineering and regeneration
Wang, Y., Chen, S., Yan, Z., & Pei, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-018-0264-9 · Cited by 69
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
Sirhan, Z., Thyagarajan‐Sahu, A., & Sahu, R. P. (2022) · Military Medical Research · doi:10.1186/s40779-022-00401-3 · Cited by 67
Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer
Cleary, J. M., & Shapiro, G. I. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0091-6 · Cited by 65
Overcoming Drug Resistance in Patients with Metastatic Breast Cancer
Wong, S. T.-L., & Goodin, S. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.8.954 · Cited by 63
Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155
Lee, D. W., Futami, M., Carroll, M. P., Feng, Y., Wang, Z., Fernandez, M., Whichard, Z. L., Chen, Y., Kornblau, S. M., Shpall, E. J., et al. (2012) · Oncogene · doi:10.1038/onc.2011.579 · Cited by 63
HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer
Ahmad, I., Patel, R., Singh, L. B., Nixon, C., Seywright, M. M., Barnetson, R. J., Brunton, V. G., Muller, W. J., Edwards, J., Sansom, O. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101263108 · Cited by 63
ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
Elizalde, P. V., Russo, R. I. C., Chervo, M. F., & Schillaci, R. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0360 · Cited by 68
Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN
Aghazadeh, S., & Yazdanparast, R. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.05.009 · Cited by 64
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A., Bachelot, T., Chan, S., Han, H., Jerusalem, G., Urban, P., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4596-7 · Cited by 53
RETRACTED ARTICLE: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
Liu, Y., Xu, J., Choi, H. H., Han, C., Fang, Y., Li, Y., der Jeught, K. V., Xu, H., Zhang, L., Frieden, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07264-0 · Cited by 62
Retracted
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy
Fan, X., Brezski, R. J., Fa, M., Deng, H., Greenplate, A. R., Gonzalez, A. O., Dubinsky, W. P., Strohl, W. R., Jordan, R. E., Zhang, N., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3240 · Cited by 63
AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth
Grimshaw, K. M., Hunter, L.-J. K., Yap, T. A., Heaton, S. P., Walton, M. I., Woodhead, S. J., Fazal, L., Reule, M., Davies, T. G., Seavers, L. C. A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0986 · Cited by 64
The cardiac safety of trastuzumab in the treatment of breast cancer
Chien, A. J., & Rugo, H. S. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003627441 · Cited by 62
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
Wu, V. S., Kanaya, N., Lo, C., Mortimer, J. E., & Chen, S. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.005 · Cited by 62
HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
Spector, N. L., Xia, W., El‐Hariry, I. A., Yarden, Y., & Bacus, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1652 · Cited by 62
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
Ocaña, A., Gil-Martín, M., Antolín, S., Atienza, M., Montaño, Á., Ribelles, N., Urruticoechea, A., Falcón, A., Pernas, S., Orlando, J., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05100-z · Cited by 61
Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16Ink4a loss
Debies, M. T., Gestl, S. A., Mathers, J. L., Mikse, O. R., Leonard, T. L., Moody, S. E., Chodosh, L. A., Cardiff, R. D., & Gunther, E. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33320 · Cited by 61
Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma
Sakr, R. A., Barbashina, V., Morrogh, M., Chandarlapaty, S., de Andrade, V. P., Arroyo, C. D., Olvera, N., & King, T. A. (2010) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181d50bd5 · Cited by 61
One target, different effects: a comparison of distinct therapeutic antibodies against the same targets
Shim, H. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.10.063 · Cited by 66
Advanced HER2-positive gastric cancer: Current and future targeted therapies
Pazo-Cid, R., & Antón, A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.08.008 · Cited by 61
Clinical development of mTOR inhibitors in breast cancer
Vicier, C., Dieci, M. V., Arnedos, M., Delaloge, S., Viens, P., & André, F. (2014) · Breast Cancer Research · doi:10.1186/bcr3618 · Cited by 61
Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents
O'Connor, R. A., CLYNES, M. M., Dowling, P., O’Donovan, N., & O’Driscoll, L. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.6.805 · Cited by 63
Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway
Guo, Y. H., Chang, H., Li, J., Xu, X.-Y., Shen, L., Yu, Z., & Liu, W. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1138-9 · Cited by 61
Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2‐negative metastatic breast cancer
Gasch, C., Oldopp, T., Mauermann, O., Gorges, T. M., Andreas, A., Coith, C., Müller, V., Fehm, T. N., Janni, W., Pantel, K., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.07.005 · Cited by 61
mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®)
Vázquez‐Martín, A., Oliveras‐Ferraros, C., Barco, S. D., Martı́n-Castillo, B., & Menéndez, J. A. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0384-0 · Cited by 60
Targeting the PI3K Pathway for Cancer Therapy
Sadeghi, N., & Gerber, D. E. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.56 · Cited by 59
Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer
Okines, A. F. C., & Cunningham, D. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12450246 · Cited by 60
Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling
Wu, G., Cao, L., Zhu, J., Tan, Z., Tang, M., Li, Z., Hu, Y., Yu, R., Zhang, S., Song, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2554 · Cited by 60
Everolimus
Hasskarl, J. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_23 · Cited by 63
Methylation-mediated gene silencing as biomarkers of gastric cancer: A review
Nakamura, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.11991 · Cited by 59
PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance
Lee-Hoeflich, S. T., Pham, T. Q., Dowbenko, D., Munroe, X., Lee, J., Li, L., Zhou, W., Haverty, P. M., Pujara, K., Stinson, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0062 · Cited by 59
Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes
Gatza, M. L., Kung, H., Blackwell, K., Dewhirst, M. W., Marks, J. R., & Chi, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2899 · Cited by 59
Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
Ettl, T., Baader, K., Stiegler, C., Müller, M., Agaimy, A., Zenk, J., Kühnel, T., Gosau, M., Zeitler, K., Schwarz, S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.605 · Cited by 59
Personalizing HER2-Targeted Therapy in Metastatic Breast Cancer Beyond HER2 Status: What We Have Learned from Clinical Specimens
Nahta, R., Shabaya, S., Ozbay, T., & Rowe, D. (2009) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569209790112337 · Cited by 60
Cancer therapeutic antibodies come of age: Targeting minimal residual disease
Ben-Kasus, T., Schechter, B., Sela, M., & Yarden, Y. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.003 · Cited by 59
The Implications of Cancer Stem Cells for Cancer Therapy
Jiang, W., Peng, J., Zhang, Y., Cho, W., & Jin, K. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131216636 · Cited by 59
Novel ATP‐competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
Yamaji, M., Ota, A., Wahiduzzaman, M., Karnan, S., Hyodo, T., Konishi, H., Tsuzuki, S., Hosokawa, Y., & Haniuda, M. (2017) · Cancer Medicine · doi:10.1002/cam4.1179 · Cited by 59
Frequency of mesenchymal‐epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide‐3‐kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer
Gonzalez-Angulo, A. M., Chen, H., Karuturi, M. S., Chávez‐MacGregor, M., Tsavachidis, S., Meric‐Bernstam, F., Do, K.-A., Hortobágyi, G. N., Thompson, P. A., Mills, G. B., et al. (2012) · Cancer · doi:10.1002/cncr.27608 · Cited by 58
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
Giuliani, R., Durbecq, V., Leo, A. D., Paesmans, M., Larsimont, D., Leroy, J.-Y., Borms, M., Vindevoghel, A., Jérusalem, G., D’Hondt, V., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.019 · Cited by 58
The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy
Vázquez‐Martín, A., Oliveras‐Ferraros, C., del Barco, S., Martı́n-Castillo, B., & Menéndez, J. A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn758 · Cited by 58
Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation
Shi, Y., Fan, X., Meng, W., Deng, H., Zhang, N., & An, Z. (2014) · Breast Cancer Research · doi:10.1186/bcr3637 · Cited by 58
Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk
Tamaskovic, R., Schwill, M., Nagy‐Davidescu, G., Jöst, C., Schaefer, D. C., Verdurmen, W. P. R., Schaefer, J. V., Honegger, A., & Plückthun, A. (2016) · Nature Communications · doi:10.1038/ncomms11672 · Cited by 58
The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
Lee, J. Y., Hong, M. E., Kim, S. T., Park, S. H., Kang, W. K., Kim, K.-M., & Lee, J. (2015) · Scientific Reports · doi:10.1038/srep09289 · Cited by 57
FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in PTEN-Null T-ALL Cells
You, D., Xin, J., Volk, A. G., Wei, W., Schmidt, R., Scurti, G. M., Nand, S., Breuer, E.-K. Y., Kuo, P. C., Breslin, P., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.056 · Cited by 57
Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA
Tang, Y., Hamed, H. A., Cruickshanks, N. A., Fisher, P. B., Grant, S., & Dent, P. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076851 · Cited by 59
Understanding and circumventing resistance to anticancer monoclonal antibodies
Reslan, L., Dalle, S., & Dumontet, C. (2009) · mAbs · doi:10.4161/mabs.1.3.8292 · Cited by 57
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Bao, Y., Oguz, G., Lee, W. C., Lee, P. L., Ghosh, K., Li, J., Wang, P., Lobie, P. E., Ehmsen, S., Ditzel, H. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19704-x · Cited by 58
MicroRNA-induced drug resistance in gastric cancer
Dehghanzadeh, R., Jadidi‐Niaragh, F., Gharibi, T., & Yousefi, M. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.08.009 · Cited by 57
Mammalian target of rapamycin: Biological function and target for novel anticancer agents
Borders, E. B., Bivona, C. R., & Medina, P. J. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100020 · Cited by 56
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
Sakai, H., Tsurutani, J., Iwasa, T., Komoike, Y., Sakai, K., Nishio, K., & Nakagawa, K. (2018) · Breast Cancer · doi:10.1007/s12282-018-0861-9 · Cited by 59
Anti‐HER‐3 MAbs inhibit HER‐3‐mediated signaling in breast cancer cell lines resistant to anti‐HER‐2 antibodies
van der Horst, E. H., Murgia, M., Treder, M., & Ullrich, A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20867 · Cited by 56
Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers
Hamel, S., Bouchard, A., Ferrario, C., Hassan, S. N., Aguilar‐Mahecha, A., Buchanan, M., Quenneville, L., Miller, W. H., & Basik, M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0364-7 · Cited by 56
Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine
Coleman, N., Moyers, J. T., Harbery, A., Vivanco, I., & Yap, T. A. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s305068 · Cited by 55
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Denkert, C., Lambertini, C., Fasching, P. A., Pogue–Geile, K. L., Mano, M. S., Untch, M., Wolmark, N., Huang, C., Loibl, S., Mamounas, E. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1989 · Cited by 55
Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
Zimmerman, B. S., & Esteva, F. J. (2024) · Cancers · doi:10.3390/cancers16040800 · Cited by 56
CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells
Boulbés, D. R., Chauhan, G. B., Jin, Q., Bartholomeusz, C., & Esteva, F. J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3414-3 · Cited by 55

Authors: Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Ionis Pharmaceuticals (United States) (US)
Corresponding author: Yu, Dihua
ORCID: Lan, Keng-Hsueh
Zhou, Xiaoyan
Tan, Ming
Esteva, Francisco J.
Li, Ping
Monia, Brett P.
Hung, Mien-Chie
Yu, Dihua
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2004-08
Volume: 6
Issue: 2
Pages: 117-127
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2004.06.022
OpenAlex: W2059411043
Cited by: 1,858
References: 70
Citations by year: 2026: 19 · 2025: 29 · 2024: 35 · 2023: 82 · 2022: 52 · 2021: 50 · 2020: 60 · 2019: 56 · 2018: 66 · 2017: 68 · 2016: 88 · 2015: 109 · 2014: 119 · 2013: 125 · 2012: 123
FWCI: 43.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3272 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca060488-09)
National Cancer Institute (P01CA099031, 2R01-CA60488, P30CA016672)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: PTEN, trastuzumab, trastuzumab resistance, ERBB2, HER2-positive breast cancer, Src kinase inhibition, PI3K inhibitors, predictive biomarkers, antisense oligonucleotides
MeSH terms: Trastuzumab, Phosphoinositide-3 Kinase Inhibitors, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Activation, Enzyme Inhibitors, Female, Humans, Mice, Nude, Neoplasm Transplantation, Phosphoric Monoester Hydrolases, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Oligonucleotides, Antisense, Protein Serine-Threonine Kinases, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, src-Family Kinases, Phosphatidylinositol 3-Kinases, Tumor Suppressor Proteins, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks